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Background: The global effect of copy number and epigenetic alterations on miRNA expression in cancer is poorly
understood. In the present study, we integrate genome-wide DNA methylation, copy number and miRNA expression
and identify genetic mechanisms underlying miRNA dysregulation in breast cancer.
Results: We identify 70 miRNAs whose expression was associated with alterations in copy number or methylation, or
both. Among these, five miRNA families are represented. Interestingly, the members of these families are encoded on
different chromosomes and are complementarily altered by gain or hypomethylation across the patients. In an
independent breast cancer cohort of 123 patients, 41 of the 70 miRNAs were confirmed with respect to aberration
pattern and association to expression. In vitro functional experiments were performed in breast cancer cell lines with
miRNA mimics to evaluate the phenotype of the replicated miRNAs. let-7e-3p, which in tumors is found associated with
hypermethylation, is shown to induce apoptosis and reduce cell viability, and low let-7e-3p expression is associated
with poorer prognosis. The overexpression of three other miRNAs associated with copy number gain, miR-21-3p,
miR-148b-3p and miR-151a-5p, increases proliferation of breast cancer cell lines. In addition, miR-151a-5p enhances
the levels of phosphorylated AKT protein.
Conclusions: Our data provide novel evidence of the mechanisms behind miRNA dysregulation in breast cancer.
The study contributes to the understanding of how methylation and copy number alterations influence miRNA
expression, emphasizing miRNA functionality through redundant encoding, and suggests novel miRNAs important
in breast cancer.Background
MicroRNAs (miRNAs) are small, non-coding RNA mole-
cules that regulate gene expression at a post-transcriptional
level by controlling mRNA stability and translation. They
are encoded either in the introns of protein-coding host
genes or independently in intergenic regions [1]. The initial
primary miRNA transcript can function as a polycistronic
transcript giving rise to several functional miRNAs. The 18* Correspondence: v.n.kristensen@medisin.uio.no
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reproduction in any medium, provided the orto 24 nucleotide long mature miRNA is spliced from a hair-
pin structure where the two complementary strands both
can function as regulators. In the mature sequence, the
nucleotides 2 to 8 are crucial as they constitute the ‘seed’
sequence which is important for target recognition and
binding. Similarities in the seed sequence are used to
group miRNAs into families [2].
In the normal cellular context, miRNAs may act as
genetic switches or fine-tuners [3]. Aberrant expression
of miRNAs has frequently been reported in cancer [4-7]
and miRNAs are thus suggested to play potential onco-
genic or tumor-suppressive roles. In breast cancer, altered
miRNA expression has been associated with, for example,d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[4,11,12] and metastasis [13-16]. The underlying mecha-
nisms of aberrant miRNA expression are poorly understood,
but likely causes include DNA copy number aberrations,
mutations, epigenetic aberrations, dysregulation of tran-
scription factors targeting miRNAs and alterations in
the miRNA biogenesis pathway [17]. A recent example
of the latter was the finding that EGFR can modulate
miRNA maturation in response to hypoxia [18]. One of
the very first associations of miRNA deregulation with
human cancer was with the discovery of deletion and
subsequent down-regulation of the MIR15 and MIR16
genes at 13q14 in chronic lymphocytic leukemia [19].
Later, several reports have followed linking miRNA genes
and their expression to genomic regions associated with
gain and loss in cancer [20-22]. In a recent study, miRNAs
were shown to be over-represented in copy-altered com-
pared to copy-neutral regions in breast cancer, although
the effect on miRNA expression was not incisive [23].
DNA methylation is an epigenetic modification where
methyltransferases add methyl groups to cytosine resi-
dues followed by guanines (CpGs). CpG islands are CpG
rich regions often found in gene promoters, and the
methylation state of a CpG island often correlates with
the gene expression state with hypermethylation associ-
ated with decreased expression and hypomethylation
with increased expression [24]. Recently, aberrant DNA
methylation of miRNA genes has received attention and
been identified as an emerging mechanism of miRNA
deregulation in cancer [25]. In particular, hypermethylation
of miRNA promoters has been reported, but also hypome-
thylation has been recognized as a mechanism leading to
disrupted miRNA expression in cancer [14,15,26-32].
In this study, we investigated the combined effect of
copy number and methylation on miRNA expression in
breast cancer. The analysis revealed complementary
aberration patterns across patients and led to the dis-
covery of novel tumor suppressing and oncogenic miRNA
candidates, of which four selected miRNAs were con-
firmed by functional studies in vitro.
Results
Integrated analysis reveals miRNAs altered in-cis by copy
number or DNA methylation
To identify potential oncogenic or tumor suppressor
miRNAs, two scenarios of particular biological relevance
were considered. In the first scenario, lower expression is
due to loss of genetic material or hypermethylation (silen-
cing in-cis effects), and in the second, higher expression
is due to gain of genetic material or hypomethylation
(activating in-cis effects). Considering 575 miRNA gen-
omic loci (corresponding to 461 unique and detectable
mature miRNAs), 70 miRNAs were classified as in-cis
miRNAs, that is, methylation or copy number aberrationswere associated with the miRNA expression level (Figure 1;
Additional file 1). For silencing in-cis effects, we consid-
ered hypermethylation alone, loss alone, and hypermethy-
lation and loss combined. For activating in-cis effects, we
considered hypomethylation alone, gain alone and finally
hypomethylation and gain combined. This allowed the
contribution of both methylation and copy number aber-
rations to be captured, thus enabling the identification
of the main force driving aberrant miRNA expression.
Additional file 2 shows an outline of the approach.
Among the 70 in-cis miRNAs, 24 were associated mainly
with copy number aberrations, 22 mainly with methylation
aberrations and 24 miRNAs with a combination of copy
number and methylation aberrations (see Additional file 1
for details). Figure 2 shows examples of identified in-cis
miRNAs from the different aberration categories. A
total of 59 in-cis miRNAs had an association between
hypomethylation or gain and increased expression, and
19 had an association between hypermethylation or loss
and decreased expression. Eight miRNA loci showed both
silencing and activating in-cis effects.
In-cis miRNAs were most frequently found to reside
on chromosome 1 (14%), 8 (10%), 13 (13%) and 17 (10%),
all of which are commonly associated with aberrations in
breast cancer [35]. The average Spearman correlation
between copy number and expression for miRNAs that
were mainly copy number driven was 0.44 (ranging from
0.22 to 0.65). For the miRNAs mainly driven by methy-
lation aberrations the average Spearman correlation be-
tween methylation status and expression was -0.50 (ranging
from -0.65 to -0.31; Additional file 1).
Complementary aberration pattern of miRNAs with
identical seed sequence
Among the 70 in-cis miRNAs, five families were identi-
fied encompassing a total of 13 in-cis miRNAs (Table 1).
All members of each family have identical seed sequence,
but are frequently encoded on different chromosomes
(Figure 1). Due to the identical seed sequence, miRNAs
in the same family may share common target genes [2].
Several of the tumors had an aberration of at least one
of the miRNAs in each family (Additional file 3), show-
ing a complementary aberration pattern for these miR-
NAs in breast cancer. For example, the in-cis miRNAs
miR-30b-5p/miR-30d-5p, miR-30c-5p and miR-30e-5p
are encoded on chromosomes 8, 6, and 1, respectively.
Several of the tumor samples were found to have gain
or hypomethylation of at least one of these miRNA
loci (Additional file 3). Similarly, miR-92a-3p and miR-
92b-3p, encoded on chromosomes 13 and 1, respect-
ively, were associated with hypomethylation and gain
leading to increased expression. In addition, miR-106b-
5p (chromosome 7), miR-17-5p and miR-20a-5p (both
on chromosome 13) were associated with hypomethylation
Figure 1 (See legend on next page.)
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Figure 1 Genomic localization of the 70 in-cis miRNAs. The 70 in-cis miRNAs were identified using Wilcoxon rank-sum tests to identify differential
miRNA expression between patients in different aberration groups. miRNAs are color coded according to main aberration type of the miRNA locus
(see legend). The number in parentheses under aberration type represents the number of in-cis miRNAs in the given aberration category.
Inter-chromosomal and intra-chromosomal lines (the latter is seen as independent lines on chromosomes 8 and 13) link in-cis miRNAs to
other members of the same miRNA family (see legend). miRNA family annotation is taken from TargetScan (release 6.2) [2,33]. The plot was
made using the Circos software package [34].
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addition to miR-92a-3p, are part of the paralogous miR-
17-92 and miR-106b-25 clusters that have been found
to be upregulated and to have an oncogenic function in
several cancer types, including breast cancer [36,37]. This
complementary mode of aberrations further suggests that
these miRNAs play an important oncogenic role in breast
cancer, and shows that both hypomethylation and gain
are mechanisms that increase their expression across
the patients.miR-135b-5p
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Table 1 In-cis miRNA families and family members
miRNA familya miRNA MIMAT Chromosomal location (hg19) Mature sequence (5′-3′ direction)b Aberrationc
miR-148ab-3p/152 miR-148a-3p MIMAT0000243 7p15.2 UCAGUGCACUACAGAACUUUGU Hypermethylated/hypogain
miR-148b-3p MIMAT0000759 12q13.13 UCAGUGCAUCACAGAACUUUGU Gain
miR-17/17-5p/20ab/20b-5p/93/106ab/427/518a-3p/519d miR-106b-5p MIMAT0000680 7q22.1 UAAAGUGCUGACAGUGCAGAU Hypogain
miR-17-5p MIMAT0000070 13q31.3 CAAAGUGCUUACAGUGCAGGUAG Hypomethylated/hypogain
miR-20a-5p MIMAT0000075 13q31.3 UAAAGUGCUUAUAGUGCAGGUAG Hypomethylated/hypogain
miR-130ac/301ab/301b/301b-3p/454/721/4295/3666 miR-130b-3p MIMAT0000691 22q11.21 CAGUGCAAUGAUGAAAGGGCAU Hypogain
miR-454-3p MIMAT0003885 17q22 UAGUGCAAUAUUGCUUAUAGGGU Hypogain
miR-30abcdef/30abe-5p/384-5p miR-30b-5p MIMAT0000420 8q24.22 UGUAAACAUCCUACACUCAGCU Gain
miR-30c-5p MIMAT0000244 6q13 UGUAAACAUCCUACACUCUCAGC Hypomethylated
miR-30d-5p MIMAT0000245 8q24.22 UGUAAACAUCCCCGACUGGAAG Gain/Hypogain
miR-30e-5p MIMAT0000692 1p34.2 UGUAAACAUCCUUGACUGGAAG Gain
miR-25/32/92abc/363/363-3p/367 miR-92a-3p MIMAT0000092 13q31.1 UAUUGCACUUGUCCCGGCCUGU Hypomethylated/hypogain
miR-92b-3p MIMAT0003218 1q22 UAUUGCACUCGUCCCGGCCUCC Gain/Hypogain
aFrom TargetScan (release 6.2) [2,33].
bFrom miRBase (release 18) [38]. Nucleotides in bold highlight the seed sequence.
cAccording to Wilcoxon rank-sum tests. Aberrations highlighted in bold indicate main aberration type. Hypogain, significant in tests grouping samples with hypomethylation and/or gain.
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families with members residing on different chromosomes
were represented among the replicated miRNAs; miR-Table 2 In-cis miRNAs confirmed in the replication cohort
miRNA MIMAT id Chromo
let-7e-3p MIMAT0004485 19q13.4
miR-125a-5p MIMAT0000443 19q13.4
miR-130b-3p MIMAT0000691 22q11.2
miR-135b-5p MIMAT0000758 1q32.1
miR-141-3p MIMAT0000432 12p13.3
miR-142-3p MIMAT0000434 17q22
miR-142-5p MIMAT0000433 17q22
miR-148a-3p MIMAT0000243 7p15.2
miR-148a-5p MIMAT0004549 7p15.2
miR-148b-3p MIMAT0000759 12q13.1
miR-151a-3p MIMAT0000757 8q24.3
miR-151a-5p MIMAT0004697 8q24.3
miR-15b-3p MIMAT0004586 3q25.33
miR-16-2-3p MIMAT0004518 3q25.33
miR-17-3p MIMAT0000071 13q31.3
miR-17-5p MIMAT0000070 13q31.3
miR-182-3p MIMAT0000260 7q32.2
miR-186-5p MIMAT0000456 1p31.1
miR-190b MIMAT0004929 1q21.3
miR-193b-3p MIMAT0002819 16p13.1
miR-19a-3p MIMAT0000073 13q31.3
miR-19b-3p MIMAT0000074 13q31.3
miR-200c-3p MIMAT0000617 12p13.3
miR-200c-5p MIMAT0004657 12p13.3
miR-205-5p MIMAT0000266 1q32.2
miR-21-3p MIMAT0004494 17q23.1
miR-219-5p MIMAT0000276 6p21.32
miR-29b-2-5p MIMAT0004515 1q32.2
miR-301a-3p MIMAT0000688 17q22
miR-30b-3p MIMAT0004589 8q24.22
miR-30c-2-3p MIMAT0004550 6q13
miR-30c-5p MIMAT0000244 6q13
miR-30d-3p MIMAT0004551 8q24.22
miR-30d-5p MIMAT0000245 8q24.22
miR-423-3p MIMAT0001340 17q11.2
miR-423-5p MIMAT0004748 17q11.2
miR-454-3p MIMAT0003885 17q22
miR-484 MIMAT0002174 16p13.1
miR-93-3p MIMAT0004509 7q22.1
miR-93-5p MIMAT0000093 7q22.1
miR-9-3p MIMAT0000442 15q26.1130b-3p/miR-454-3p on chromosomes 22 and 17, respect-
ively, and miR-30c-5p/miR-30d-5p on chromosomes 6
and 8, respectively.somal location (hg19) Replicated aberration type
1 Hypermethylation
1 Hypermethylation
1 Gain
Hypomethylation
1 Gain
Hypomethylation
Hypomethylation
Hypermethylation
Hypermethylation
3 Gain
Gain
Gain
Gain and hypomethylation
Hypomethylation
Hypomethylation
Hypomethylation
Gain
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Hypomethylation
2 Gain
Hypomethylation
Hypomethylation
1 Gain and hypomethylation
1 Gain
Hypomethylation
Gain
Gain
Gain
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Hypomethylation
Hypomethylation
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1 Gain
Gain
Gain
Gain
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similar copy number aberration in both the replication
and discovery cohort. These 25 copy number-replicated
miRNAs were among those with the highest copy number-
expression correlation in both cohorts when considering
all in-cis miRNAs (Additional file 4a). miR-186-5p was
the only replicated miRNA associated with copy num-
ber loss and decreased expression. Interestingly, it was
also associated with upregulation in samples with gain,
and thus one of the in-cis miRNAs with an ambiguous
aberration pattern.
Furthermore, in the replication cohort, 14 miRNAs
were found associated with hypomethylation and increased
expression, and four miRNAs were associated with hyper-
methylation and decreased expression, in agreement with
those observed in the discovery cohort. Two miRNAs,
miR-15b-3p and miR-200c-3p, were associated with both
gain and hypomethylation. The Spearman correlation be-
tween methylation status and miRNA expression in the dis-
covery and replication cohorts was 0.56 (Additional file 4b).
Replicated in-cis miRNAs and associations with clinical
parameters
To investigate whether the expression of the replicated
in-cis miRNAs was significantly associated with clinical
or molecular subgroups in breast cancer, Wilcoxon rank-
sum tests were used. A false discovery rate (FDR) adjusted
threshold of P < 0.05 was considered as statistically signifi-
cant. The parameters investigated were TP53 mutation
status, histological grade, molecular subtypes (luminal
versus basal-like), ER and human epidermal growth factor
receptor 2 (HER2) status. The in-cis miRNAs consistently
associated with clinical parameters in both cohorts and
the associated P-values are shown in Table 3 (those associ-
ated with clinical parameters in either one of the cohorts
are shown in Additional file 5). miR-19a-3p, which was
associated with hypomethylation, was found up-regulated
in TP53 mutated, ER-negative and basal-like samples.
miR-93-5p and miR-30c-2-3p associated with gain and
hypomethylation, respectively, were found to be inversely
associated with grade; miR-93-5p expression increasing
with increasing grade, and miR-30c-2-3p expression de-
creasing with increasing grade. Interestingly, miR-93-5p
expression was previously found positively associated with
increasing grade, and mir-30a-3p/5p expression was in-
versely associated with grade [39]. As expected, there
was considerable overlap between miRNAs differentially
expressed between the luminal and basal-like subtypes
and the ER-positive and -negative tumors. For example,
miR-125a-5p and miR-190b showed increased expres-
sion in luminal and ER-positive tumors compared to
basal-like and ER-negative tumors, whereas miR-9-3p,
miR-17-5p and miR-19a-3p showed the opposite expres-
sion pattern (Table 3).In vitro functional studies of the candidate miRNAs reveal
importance for cancer cell survival
To study the functional significance of the replicated
in-cis miRNAs, we performed miRNA gain-of-function
studies in three breast cancer cell lines using miRNA
mimics. The KPL-4 and JIMT-1 cell lines used are ER-
negative, while MCF-7 is an ER-positive cell line. Cell
viability, proliferation, phosphorylated AKT levels (p-AKT)
and apoptosis (cleaved poly (ADP-ribose) polymerase
(cPARP)) were used as endpoints. Of the 41 in-cis miR-
NAs tested, four miRNAs in particular, miR-21-3p,
miR-148b-3p, miR-151a-5p and let-7e-3p, showed sig-
nificant and consistent associations between aberration
patterns in the breast cancer tumors and phenotypic
effects when overexpressed in cell lines.
The coding sequence of miR-21-3p on chromosome
17q23.1 was associated with gain and subsequent higher
expression in >35% of the patient samples in both cohorts
(Additional file 6a; P < 0.001 for both cohorts). Overex-
pression of miR-21-3p resulted in increased proliferation
in the breast cancer cell lines KPL-4 and MCF-7, as mea-
sured by increased levels of the proliferation marker Ki67
(Figure 3a). In addition, the levels of phosphorylated AKT
protein were increased as a result of miR-21-3p overex-
pression in the KPL-4 and JIMT-1 cell lines (although not
significant), indicating enhanced activity of the AKT path-
way (Figure 3b).
Patients with miR-151a-5p gain showed significantly
higher expression of this miRNA (Additional file 6b;
P < 0.001 and P = 0.001 in the discovery and replication
cohorts, respectively). Proliferation was significantly
increased when overexpressing miR-151a-5p in the MCF-7
cell line, and increased proliferation was also evident in
the KPL-4 and JIMT-1 cell lines (Figure 3a). Further-
more, miR-151a-5p overexpression led to an increase
of p-AKT levels in the JIMT-1 and KPL-4 cell lines
(Figure 3b). Thus, it is possible that miR-151a-5p directly
or indirectly activates the AKT pathway and subsequently
cell proliferation.
miR-148b-3p was associated with significantly higher
expression in patients with gain (Additional file 6c;
P = 0.002 and P = 0.008 in the discovery and replication
cohorts, respectively). Overexpression of miR-148b-3p sig-
nificantly increased cell proliferation in the KPL-4 cell
line, and an increased effect on proliferation was also seen
in the MCF-7 and JIMT-1 cell lines (Figure 3a). Interest-
ingly, miR-148b-3p was one of the miRNAs differen-
tially expressed between luminal and basal-like subtypes
(Table 3), showing higher expression in luminal samples
compared to basal-like samples (Figure 4a).
Hypermethylation of the let-7e-3p miRNA promoter
on chromosome 19q13.41 was associated with decreased
let-7e-3p expression (Additional file 6d; P = 0.002 and
P = 0.001 in the discovery and replication cohorts,
Table 3 Replicated in-cis miRNAs and associations with clinical parameters
miRNA Chromosomal location
(hg19)
Direction Associated miRNA
aberration
P-value (FDR-corrected,
discovery cohort)
P-value (FDR-corrected,
replication cohort)
TP53 status (wild-type versus mutant) miR-19a-3p 13q31.3 Up in TP53 mutated samples Hypomethylation 7.5E-03 9.1E-03
Grade (1, 2 and 3) miR-30c-2-3p 6q13 Decreasing with grade Hypomethylation 1.7E-02 2.8E-02
miR-93-5p 7q22.1 Increasing with grade Gain 4.4E-03 4.2E-02
ER status (positive (+) versus negative (-)) miR-9-3p 15q26.1 Down in ER+/up in ER- Gain 9.0E-04 4.1E-03
miR-17-5p 13q31.3 Down in ER+/up in ER- Hypomethylation 1.5E-02 2.9E-03
miR-19a-3p 13q31.3 Down in ER+/up in ER- Hypomethylation 2.9E-02 2.1E-05
miR-93-5p 7q22.1 Down in ER+/up in ER- Gain 3.8E-02 2.7E-02
miR-130b-3p 22q11.21 Down in ER+/up in ER- Gain 3.5E-02 5.0E-02
miR-30c-2-3p 6q13 Up in ER+/down in ER- Hypomethylation 4.9E-02 2.4E-02
miR-125a-5p 19q13.41 Up in ER+/down in ER- Hypermethylation 1.1E-02 3.1E-03
miR-190b 1q21.3 Up in ER+/down in ER- Hypomethylation 3.5E-07 3.0E-02
Luminal versus basal-like subtype miR-125a-5p 19q13.41 Up in luminal/down in basal-like Hypermethylation 6.4E-03 1.3E-03
miR-148b-3p 12q13.13 Up in luminal/down in basal-like Gain 1.6E-05 1.0E-02
miR-190b 1q21.3 Up in luminal/down in basal-like Hypomethylation 1.6E-05 1.7E-04
miR-193b-3p 16p13.12 Up in luminal/down in basal-like Gain 2.5E-04 4.0E-06
let-7e-3p 19q13.41 Up in luminal/down in basal-like Hypermethylation 1.5E-02 8.3E-03
miR-9-3p 15q26.1 Down in luminal/up in basal-like Gain 2.4E-05 4.9E-03
miR-17-3p 13q31.3 Down in luminal/up in basal-like Hypomethylation 2.5E-05 1.9E-04
miR-17-5p 13q31.3 Down in luminal/up in basal-like Hypomethylation 1.8E-04 1.2E-04
miR-19b-3p 13q31.3 Down in luminal/up in basal-like Hypomethylation 2.8E-05 4.0E-06
miR-19a-3p 13q31.3 Down in luminal/up in basal-like Hypomethylation 1.4E-04 4.0E-06
miR-135b-5p 1q32.1 Down in luminal/up in basal-like Hypomethylation 1.6E-05 2.8E-03
miR-142-5p 17q22 Down in luminal/up in basal-like Hypomethylation 8.6E-03 1.4E-02
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Figure 3 In-cis miRNAs show functional effects when overexpressed. Breast cancer cell lines were transfected with miRNA mimics (20 nM)
and assayed for (a) cell proliferation (Ki67), (b) phosphorylated AKT (p-AKT) levels, (c) cell viability and (d) apoptosis (cleaved PARP (cPARP)),
72 hours after transfection. The dashed lines indicate cut-off points that were considered significant (see Materials and methods). Asterisks denote
significant effects. The data for cell viability are from two replicate experiments with error bars showing standard deviations.
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viability (Figure 3c), and induced apoptosis (Figure 3d) in
the KPL-4 and JIMT-1 cell lines. let-7e-3p was higher
expressed in luminal samples compared to basal-like
samples (Figure 4b). It was also found significantly more
highly expressed in ER-positive compared to ER-negative
samples in the replication cohort (Additional file 5). Fur-
thermore, in the discovery cohort, low expression of let-
7e-3p was associated with poorer prognosis (Figure 5;
log-rank test P = 0.032). Statistical significance was not
found in the replication cohort (P = 0.170).
Gene expression (anti-)correlated to the candidate miRNAs
To decipher the biological processes the four candidate
miRNAs might regulate, we explored the highest corre-
lated genes associated with these miRNAs. For this task,
a miRNA-mRNA expression correlation analysis calculating
the Spearman correlation for each miRNA to all genes was
performed. Both positive (Spearman’s rho >0.3) and nega-
tive (Spearman’s rho < -0.3) correlations were considered,but only those consistently correlated in the two cohorts.
The numbers of correlated genes were 277 for miR-148b-
3p, 53 for let-7e-3p, 32 for miR-21-3p, and 22 genes for
miR-151a-5p (Additional file 7).
Two approaches were used to characterize the genes
correlated with the candidate miRNAs. First, Ingenuity
Pathway Analysis (IPA) was used to identify networks
associated with these genes. Then, for each candidate
miRNA, the positively or negatively correlated genes were
expanded based on co-expression using the Search-based
Exploration of Expression Compendium (SEEK), and the
set of co-expressed genes thus identified was used for
functional enrichment analysis. This resulted in Gene
Ontology biological process terms found enriched among
the genes co-expressed with the genes correlated to the
miRNAs. Additional file 8 lists the SEEK results.
miR-148b-3p expression was correlated to several genes
associated with cancer-related biological functions, such
as growth, proliferation and cell death, according to IPA.
For example, EGFR, ERBB3, FAS and CCND2 expression
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file 9a). The SEEK-identified genes co-expressed with
the negatively correlated genes showed enrichment of
processes related to the Wnt pathway and motility. The
genes co-expressed with the positively correlated genes1.0
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Figure 5 Kaplan-Meier curves showing relapse-free survival
when dividing samples into high and low let-7e-3p expression
groups. The ‘low’ group denotes samples with expression below
the median (n = 43) and the ‘high’ group contains samples with
expression above the median (n = 43). The P-value is from a log-rank
test. The plot shows survival data of the discovery cohort.were enriched for processes related to the electron
transport chain and ATP synthesis.
For let-7e-3p, cancer-associated genes such as MAPK1
and EZH2 were among the negatively correlated genes,
and PURA, ERCC1 and MAPT were among the posi-
tively correlated ones (Additional file 9b). The top net-
works according to IPA were cell cycle, gene expression,
cancer, gastrointestinal disease and hepatic system disease.
The SEEK-identified genes co-expressed with the nega-
tively correlated genes were enriched for various cell
cycle- and mitosis-related biological processes. This is
consistent with the here demonstrated ability of let-7e-3p
to induce apoptosis and inhibit cell viability when overex-
pressed in breast cancer cells.
There were mainly positively correlated genes associated
with the expression of miR-21-3p, and the biological func-
tions of the related networks were both disease and motil-
ity related according to IPA (Additional file 9c). Using
SEEK, migration was consistently identified when consid-
ering the positively correlated genes, in addition to various
vasculature-related processes.
miR-151a-5p expression was correlated to 22 genes in
the discovery and replication cohort, however, including
only one negatively correlated gene (PAPLN). No net-
work was found for the correlated genes according to
IPA. SEEK identified processes related to motility and
lipid kinase activity associated with the positively corre-
lated genes. One of these genes, PTK2, is associated with
the AKT pathway [40]. These findings could be coupled
to the here demonstrated increased proliferation and
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miR-151a-5p in cell lines (Figure 3).
Discussion
The contribution of miRNA deregulation to cancer
development and progression has become increasingly
evident in recent years. However, a complete under-
standing of the causes of deregulation is still lacking.
The aim of this study was to get a deeper insight into
the underlying mechanisms of miRNA deregulation in
breast cancer by integrating different layers of data
from both the DNA and RNA levels. By considering
two well-known mechanisms - DNA methylation and
copy number alterations - we wanted to identify miR-
NAs affected by such alterations at the genomic and
epigenetic levels that were further reflected in miRNA
expression. This could indicate selection for activation
or inactivation in the tumors. Alterations at the genomic
copy number level that are subsequently reflected in RNA
expression have been previously reported in cancer for
miRNAs as well as other non-coding RNA species such as
long non-coding RNAs and small nucleolar RNAs [41,42].
In contrast to most studies, which have focused on either
copy number or methylation aberrations separately, this
study sought to investigate both mechanisms simultan-
eously. Despite the use of different copy number platforms
and technologies to assess methylation status, 41 miRNAs
were consistently found associated with DNA methylation
or copy number alteration and association with expression
in the discovery and replication cohort. The Agilent
miRNA microarrays that were used for expression pro-
filing of the discovery and replication cohort have been
shown to have a high performance in a comprehensive
comparison study of different miRNA array technolo-
gies [43]. Furthermore, miRNA array expression valid-
ation by real-time PCR has previously been performed
for a selection of the miRNAs in the discovery cohort,
showing good correlation between array and real-time
PCR (average Pearson correlation of 0.72) [4].
Among the in-cis miRNAs, some were shown to be
dominated either by copy number or methylation alter-
ations, but many were driven by a combination of both
mechanisms across the patients. Interestingly, this dualism
in aberrations has previously been observed in mRNA
transcriptome data of glioblastoma and ovarian cancer
[44], suggesting that it is an important mechanism in
cancer. Another mechanism that may impact the role of
miRNAs in cancer is somatic mutations located in the
miRNA itself or in the miRNA binding site of a target
mRNA. This could ultimately either strengthen or ham-
per the miRNA-mRNA binding and thus interfere with
the miRNA regulatory role. Furthermore, with the rela-
tive high somatic mutation rate found in several can-
cers, including breast cancer [45], one may hypothesizethat the combination of mutation and, for example,
copy number alteration may occur in tumors. The large
amounts of sequencing data that are being generated
will shed new light on the prevalence of this in cancer.
The genomic distribution (intronic versus intergenic),
the redundancy in being coded at various loci and chro-
mosomes, and the sequence similarities of miRNAs allow-
ing them to target the same genes are essential attributes
to keep in mind when trying to understand miRNA-
driven regulation in an evolutionary perspective. As one
miRNA can have several targets, selection may act in an
efficient manner; by altering one miRNA, the down-
stream effects may be vast. We were interested in map-
ping and categorizing aberration patterns that were seen
across breast cancer tumors and causing phenotypic
effects. Considering all miRNA genomic loci was there-
fore important. One could hypothesize that miRNAs with
functional significance in cancer with more than one
genomic origin could have ‘complementary’ regulation,
that is, there are several genomic loci where an aberra-
tion can ‘hit’ in order to alter the expression of that par-
ticular miRNA. Indeed, for five miRNA families we found
aberrations of several members located at different chro-
mosomes that had a complementary aberration pattern
across the patients in the discovery cohort. Furthermore,
two of these families were consistently found in the in-
dependent replication cohort. For example, the miR-30
family had complementary aberrations in several mem-
bers associated with hypomethylation and gain. Members
of this family have previously been associated with gain
and increased expression [39], and found up-regulated
in ER-positive breast cancer samples [5]. In this study,
miR-30c-2-3p was found consistently upregulated in
ER-positive compared to ER-negative tumors. Interest-
ingly, although associated with hypomethylation and
gain resulting in upregulation, miRNAs in this family
have previously also been suggested to play a tumor
suppressor role; ectopic expression of miR-30 in breast-
tumor initiating cells inhibited their self-renewal capacity
and induced apoptosis [46]. In addition, miR-30 family
members have been shown to be important for inducing
cellular senescence by targeting the oncogenic transcrip-
tion factor MYBL2 in cervical carcinoma cell lines [47].
Thus, the miR-30 family miRNAs may play dualistic
roles in cancer.
Although often residing on different chromosomes,
miRNA members of the same family have likely arisen
from ancient gene duplication events [48], and their regu-
latory regions may be conserved between families. Thus,
members of the same family may share transcription
factors. For example, the miR-17 in-cis family that in
this study was found associated with gain and hypomethy-
lation of members encoded on chromosomes 7 and 13,
has previously been shown to be a target of the c-Myc
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scriptional control elements is another mechanism for
regulation of miRNA family members.
An example of miRNA redundancy in the genome is
miR-125a-5p and miR-125b. The former miRNA resides
on chromosome 19 and was associated with hyperme-
thylation in both the discovery and replication cohort.
miR-125b, which is encoded on chromosome 11 and 21,
was previously reported as hypermethylated in breast
cancer and suggested to function as a tumor suppressor
[31]. miR-125a-5p and miR-125b have identical seed se-
quence and may thus target some of the same genes.
Interestingly, Scott et al. [51] showed that ERBB2 and
ERBB3 were targeted by miR-125a and miR-125b. An-
other validated target gene of miR-125b, ETS1, is a proto-
oncogene [31], shown to cooperate with mutant p53 to
selectively regulate promoters [52].
In-cis miRNAs previously associated with cancer
Several of the replicated in-cis miRNAs have previously
been associated with breast cancer, such as miR-93-5p
[37], miR-193b-3p [9], miR-301a-3p [11] and miR-423-
3p/-5p [53,54]. In addition, miRNAs found differentially
expressed between ER status and molecular subtype have
previously been identified [4,39]. Interestingly, miR-93-5p,
which was up-regulated in ER-negative compared to
ER-positive tumors, has been shown to downregulate
the ER protein and inhibit estrogen-induced growth of
breast cancer cell lines [9]. Two of the miRNAs associ-
ated with methylation aberrations in this study confirmed
previous findings in cancer, such as hypermethylation of
miR-148a-3p in breast cancer [14] and miR-199a-5p in
testicular cancer [26]. In two recent studies, the role of
miRNA expression during breast cancer progression was
assessed, suggesting that deregulation of miRNA expres-
sion is an early event seen already during transition
from normal to benign lesions [55,56]. Among the
miRNAs associated with gain and hypomethylation in
our study, 10 were reported upregulated in malignant
compared to normal breast tissue in the latter studies: miR-
15b-5p, miR-17-5p, miR-19b-3p, miR-20a-5p, miR-30d-5p,
miR-106b-5p, miR-130b-3p, miR-141-3p, miR-200c-3p and
miR-766-3p [55,56]. Furthermore, two miRNAs, miR-145-
5p and miR-199a-5p, associated with hypermethylation and
loss, were reported downregulated in malignant compared
to normal tissue [55].
Four candidate miRNAs showing functional effects
Four in-cis miRNAs, let-7e-3p, miR-21-3p, miR-151a-5p
and miR-148b-3p, associated with in vivo aberrations,
showed significant effects in vitro after functional experi-
ments. The three former miRNAs have, to our know-
ledge, not been previously associated with breast cancer.
Interestingly, both let-7e-3p and miR-21-3p are so-called‘star’-miRNAs (that is, let-7e* and miR-21*). This anno-
tation was previously used in the miRNA nomenclature
to denote the miRNA sequence in the miRNA duplex
that had the lowest expression and was thought to be
degraded during strand selection, and thus not functional.
However, it was later shown that the strand selection
process is highly regulated, showing tissue-/cell-/
condition-specific modulation [57]. Furthermore, the
ratio of the expressed molecules from each strand varies
from both strands being expressed at comparable levels
to only one being expressed [57]. Though the two ma-
ture miRNAs originating from the same duplex have
different target genes, they may function in a coopera-
tive manner contributing to post-transcriptional gene
silencing when co-expressed [57].
The candidate miRNAs let-7e-3p and miR-21-3p were
interesting as they have been much less described than
their frequently cancer-associated -5p counterparts. miR-
21-5p (miR-21) has been assigned an oncogenic role and
associated with overexpression in various cancer types. In
breast cancer, miR-21-5p overexpression has been linked
to advanced stage, metastasis and poor prognosis [58].
The MIR21 gene resides on chromosome 17q23.1, and
miR-21-5p overexpression was in a previous study linked
to amplification of this genomic region [59]. Our func-
tional data suggest that miR-21-3p may play an oncogenic
role in breast cancer, in addition to its well-annotated
miR-21-5p counterpart. Previous studies have shown
that miR-21-5p targets PTEN, which further leads to
increased p-AKT levels [60,61]. As miR-21-3p overex-
pression in this study also showed an increase in p-AKT
levels, this may implicate that miR-21-5p/3p originating
from the same precursor could have a coordinate way
of operating.
The let-7 family of miRNAs is evolutionarily conserved
across animal species, and humans have 10 mature let-7
family sequences, produced from 13 precursor sequences
encoded on several chromosomes [62]. Several let-7 family
members have been reported as down-regulated and thus
annotated as tumor suppressor miRNAs in various cancer
types [6,63,64]. In this study, we describe hypermethyla-
tion of the MIRLET7E promoter region associated with
decreased expression of let-7e-3p. It has been previously
shown that MIRLET7E is epigenetically repressed by ly-
sine (K)-specific demethylase 5B (JARID1B) in breast
cancer cell lines [12]. JARID1B is a transcriptional repres-
sor harboring histone demethylase activity. As cyclin D1 is
a target of let-7e-5p, the repression of let-7e-5p expression
by JARID1B was suggested to stimulate tumor cell pro-
liferation by allowing cyclin D1 expression and hence
cell cycle progression [12]. Our functional experiments
showed that overexpression of let-7e-3p had a strong
positive effect on apoptosis and a strong negative effect
on cell viability in the ER-negative cell lines. In the
Aure et al. Genome Biology 2013, 14:R126 Page 13 of 20
http://genomebiology.com/2013/14/11/R126ER-positive cell line MCF-7, the same tendency was
seen, although less pronounced. Interestingly, let-7e-3p
was found significantly downregulated in basal-like com-
pared to luminal samples in both cohorts tested. Thus, the
stronger phenotypic effects observed in the ER-negative
cell lines may be in agreement with most of the basal-like
samples also being ER negative. Furthermore, low let-7e-
3p expression was associated with a worse prognosis, and
the network analysis linked let-7e-3p to cancer-related
genes. Altogether, this suggests that let-7e-3p may also act
as a tumor suppressor in breast cancer, perhaps in particu-
lar for ER-negative or basal-like tumors. To our know-
ledge this is the first report linking this let-7e family
member to a tumor suppressor function.
miR-151a-5p is located on 8q24.3, a genomic area fre-
quently associated with gain in breast cancer [35,65] and
other cancer types [66,67]. We found high expression of
miR-151a-5p associated with gain, and functional experi-
ments showed that overexpression induced cell prolifer-
ation and also the levels of p-AKT. Altogether, this may
suggest a tumorigenic role for miR-151a-5p. This miRNA
has previously been linked to gain and subsequent up-
regulation causing cell migration and invasion in hepato-
cellular carcinoma by targeting Rho GDP dissociation
inhibitor alpha (RhoGDIA), which is a putative metasta-
sis suppressor [21].
miR-148b-3p is encoded on chromosome 12q13.13 and
was in this study associated with gain and increased ex-
pression. We showed that overexpression of miR-148b-3p
increased proliferation of breast cancer cell lines. Consist-
ently, the correlation analysis revealed both positively and
negatively correlated genes associated with cell growth
and proliferation. miR-148b-3p has been shown to target
the methyltransferase DNMT3b [68]. Interestingly, this
miRNA was recently reported upregulated in the blood
plasma of breast cancer patients and suggested as an
early detection marker [69]. However, in another study,
miR-148b was found downregulated in aggressive breast
tumors and suggested to inhibit progression [70]. This
underlines the potential context-dependent roles of miR-
NAs, and was further manifested by the fact that the family
member miR-148a was found associated with hypermethy-
lation and decreased expression in both the discovery and
replication cohort. Noteworthy, miR-148a was previously
identified as an epigenetically silenced miRNA associated
with metastasis that was reactivated when cells derived
from lymph node metastases were treated with the
demethylating agent 5-aza-2'-deoxycytidine [14]. Further
functional studies are warranted to characterize the poten-
tial oncogenic role of miR-148b-3p in breast cancer.
Conclusion
We here describe the effect of DNA methylation and
copy number alterations on miRNA expression in breastcancer. Using two independent cohorts of primary breast
cancer patients, we show that these mechanisms affect
the expression of miRNAs. Adding to the complexity
is the redundant encoding of miRNA family members,
which should be taken into account to understand miRNA
functionality in cancer. Altogether, this study portrays
underlying mechanisms of miRNA deregulation that may
contribute to breast cancer development and progression.
Materials and methods
All computational analyses were performed in R v.2.13.0
[71] unless otherwise specified. The miRNA copy num-
ber, methylation and expression data analyzed in this
work are available in Additional file 10 for the discovery
cohort and Additional file 11 for the replication cohort.
All experimental methods performed are in compliance
with the Helsinki Declaration.
Patient materials
Included in this study were primary breast carcinoma
samples from 89 patients in the MicMa cohort [72] with
data on miRNA expression, methylation, copy number
and mRNA expression. All samples were fresh frozen and
contained at least 40% tumor cells. The majority of the
tumor specimens represent tumor size T1/T2, node status
N0/N1, and histological grade 2 or 3. Tumor DNA was
extracted using an ABI 341 Nucleic Acid Purification
System (Applied Biosystems, Foster City, CA, USA) ac-
cording to the manufacturer’s protocol. Tumor RNA
was isolated using TRIzol reagent (Invitrogen, Carlsbad,
CA, USA) as previously described [73]. The molecular
subtype classification based on mRNA expression and
the clinical information is described in [74]. The study
was approved by the Norwegian Regional Committee
for Medical Research Ethics, Health region II (reference
number S-97103), and patients have given written con-
sent for the use of material for research purposes.
A total of 123 primary breast carcinoma samples from
the Danish Breast Cancer Cooperative Group (‘DBCG’)
82 b and c trial cohort [75-77] were obtained after total
mastectomy surgery and were used for the purpose of
replication. This study comprises a collection of tumor
tissues from 3,083 high-risk Danish breast cancer patients
diagnosed in the period 1982 to 1990 [75-77]. Total mast-
ectomy with partial axillary dissection was performed on
all women, and a median of seven lymph nodes was
removed from the axilla. RNA was extracted using the
Qiagen Midi kit Extraction column procedure (Qiagen
GmbH, Hilden, Germany). The study of the DBCG82bc
cohort has been approved by the Regional Ethical Com-
mittee (Journal number 20030263).
Normal breast tissue samples were available from 17
women that had undergone mammoplastic reduction at
Colosseumklinikken, Oslo, Norway [78]. These were used
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miRNA expression profiling
The miRNA expression profiling for the discovery and
replication cohort was performed using the 8x15k
‘Human miRNA Microarray Kit (V2)’ with design id
019118 from Agilent (Agilent Technologies, Santa Clara,
CA, USA). In brief, 100 ng total RNA was dephosphory-
lated, labeled and hybridized for 20 hours, following
the manufacturer’s protocol. Scanning was performed
on Agilent Scanner G2565A, signals were extracted using
Feature Extraction v9.5 and the subsequent data process-
ing was performed using the GeneSpring software v12.0
(Agilent Technologies). As the miRNA expression for the
discovery cohort was performed in duplicates per sample
(on different arrays and time points), the miRNA signal
intensities were averaged for replicate samples. For both
the discovery and replication cohort the miRNA signal
intensities were log2-transformed and for each sample,
the 90th percentile was calculated across all miRNAs
and subtracted from the miRNA expression. miRNAs
that were detected in less than 10% of the samples were
excluded. In the discovery cohort this resulted in 461
unique mature miRNAs. When a mature miRNA is
encoded several places in the genome, the genomic ori-
gin of a transcript cannot be directly inferred from
miRNA expression microarrays (unless the pre-miRNAs
are detected). To account for this, we constructed an ex-
panded 575 × 89 miRNA expression matrix that repre-
sented all the 575 miRNA genomic loci of the expressed
461 mature miRNAs using an annotation file from Agilent
eArray. All subsequent analyses were based on this
expanded matrix (Additional file 10). The miRNA ex-
pression data for the discovery cohort were published
in [4] and have been submitted to the Gene Expression
Omnibus (GEO) with accession number GSE19536. The
miRNA expression data for the replication cohort have
been submitted to GEO with accession number GSE46934.
DNA methylation analysis
Microarray
The Infinium HumanMethylation450 BeadChip microar-
rays (Illumina, San Diego, CA, USA) were used to assay
the 89 breast carcinomas in the discovery cohort and 17
normal breast samples from mammoplastic reduction.
The samples were analyzed according to the manufac-
turer's protocol and normalized using a subset quantile
normalization (SQN) approach based on the functional
annotation of probes [79]. Probes potentially containing
genetic variation with a minor allele frequency >5% in
the population of European origin (CEU, 1000 Genomes
Project) within the 20 bp of the 3’ probe sequence as
well as the nucleotides N + 1 and N + 2 of the targetsequence were omitted from the analysis. The methyla-
tion score for each CpG was represented as a value (β)
between 0 (non-methylated) and 1 (completely methylated)
according to the fluorescent intensity ratio. Methylation
probes covering CpGs within proximal promoters were
primarily used. These were defined as CpG sites located
within 1,500 bp upstream of the described transcription
start site, in the 5’ UTR or first exon [80]. Thus, probes
residing within the 3’ UTR or gene body were excluded.
Whenever a miRNA had designated probes (consulting
the annotation file), these were used. Out of the 575
miRNA loci considered, 448 had designated probes. For
miRNAs without designated probes and residing within
the introns of coding host genes (‘intronic miRNAs’),
the host gene CpG promoter probes were used (63
miRNA loci). For all remaining miRNA loci, the nearest
probe was used as an approximation (64 miRNA loci).
The methylation probe extractions resulted in 2,587
probes representing the 575 miRNA promoter loci
(Additional file 10). When more than one probe repre-
sented a miRNA, the median β-value was used. To call
aberrations in methylation status, the following method
was used: for each miRNA, the median (m) and the stand-
ard deviation (SD) of β for the normal samples were calcu-
lated. Next, the miRNA was called as hypermethylated in
a tumor sample if β exceeded m+ (2 × SD), and as hypo-
methylated if β was less than m - (2 × SD).
Pyrosequencing
The methylation status of 18 selected CpG sites for
which the genomic positions were represented by a
probe on the HumanMethylation450 BeadChip micro-
array were chosen for replication by pyrosequencing in
the replication cohort [81]. These CpG sites were located
in the promoters (within 1,500 bp before the transcription
start site) corresponding to 26 miRNAs (Additional
file 11) that were selected for replication due to their
association with methylation alteration in the discovery
cohort. DNA (500 ng) isolated from tumor tissue of 122
patients of the DBCG patient cohort and normal breast
tissue samples from 15 mammoplastic reductions [78]
were bisulfite treated using the EpiTect Fast DNA Bisulfite
Kit (Qiagen). One tumor sample did not have DNA left
and was therefore excluded from the pyrosequencing
analysis. The bisulfite converted DNA was eluted in
15 μl and diluted to a total volume of 70 μl. The PyroMark
PCR Kit reagents (Qiagen) were used in the PCR reactions
and the pyrosequencing was carried out on a PyroMark
Q96 MD system with the PyroMark Gold Q96 Reagents
(Qiagen). The quantitative DNA methylation results
were analyzed in the Q-CpG software (V.1.0.9, Biotage,
Qiagen). The PCR and sequencing primers and the PCR
and sequencing conditions are specified in Additional
file 11 together with the percentage methylation output
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site was scored as hypo- or hypermethylated using the
methylation percentage of the normal samples as a
reference defining the aberration threshold similarly as
for the discovery cohort using m ± (2 × SD) as aberra-
tion cut-off. For one assay, cg09918657 (assay 13), the
standard deviation among the normal was quite high
and the cut-off value for determining samples as hypo-
methylated was negative and was thus not assessed.
Another assay, cg27388703 (assay 16), did not score any
samples as altered. See Additional file 11 for details.
DNA copy number analysis
The DNA copy number data for the discovery cohort
were generated using Illumina Human-1 109 k BeadChip
SNP arrays (Illumina) and are described in [82]. For the
replication cohort, the Comparative Genomic Hybridization
244 k Agilent Microarrays (Agilent Technologies) were
used [83]. Copy number data were log2-transformed and
centered, and for each sample a segmentation was
performed using the Piecewise Constant Fitting (PCF)
algorithm implemented in the Bioconductor R package
Copynumber [84]. The average log-transformed copy
number was then calculated for each segment and
assigned to each probe in the segment. The trade-off
between sensitivity and specificity was set to the default
value (γ = 40) in the discovery dataset and slightly larger
(γ = 50) in the replication dataset to take into account the
array resolution (as recommended by the software instruc-
tions). In order to assign a copy number to each miRNA
locus, the segment copy number average found to cover
the miRNA was used to represent the miRNA copy num-
ber. For the discovery cohort the miRNA annotation was
for this purpose converted from the hg19 to the hg17
build by using the liftOver tool in the UCSC Genome
Browser [85]. Copy number aberrations were called by
defining miRNAs with segmented copy number values
above 0.1 as gains, and values below -0.1 as losses.
mRNA expression profiling
The mRNA expression data for the discovery dataset were
measured using Agilent 4x44K one-color oligonucleotide
arrays (Agilent Technologies) and have previously been
published [4] and submitted to GEO with accession
number GSE19783. For the replication dataset the mRNA
was measured using the Human Genome Survey Microarray
version 2.0 (Applied Biosystems), and the data were sub-
mitted to GEO with accession number GSE24117 [75,83].
Identification of in-cis miRNAs
Discovery cohort
miRNAs altered by either copy number or DNA methy-
lation level in-cis were referred to as in-cis miRNAs. To
identify in-cis miRNAs associated with hypomethylationor gain, each miRNA in each patient was assigned to
one of the two groups ‘altered’ or ‘non-altered’ based on
(i) copy number and (ii) DNA methylation. A Wilcoxon
rank-sum test was performed for each miRNA to assess
whether the miRNA expression was significantly different
in the two groups of altered and non-altered patients. The
resulting P-values were corrected for multiple compari-
son using the Benjamini-Hochberg FDR [86]. A FDR-
corrected P-value < 0.05 was considered as statistically
significant. Three tests were performed: (1) considering
aberrations on the copy number level or (2) the methy-
lation level, or (3) both. The latter category contained
samples with at least one aberration at either the copy
number or methylation level, whereas patients with no
aberrations were in the alternative group. To identify
miRNAs associated with hypermethylation or loss, an
analogous procedure was used. The statistically signifi-
cant miRNAs were visually inspected by graphing the
miRNA expression as a function of copy number or
methylation level, and only miRNAs with positive correl-
ation between copy number and expression or negative
correlation between methylation level and expression were
further considered.
Replication cohort
As genome-wide copy number was available for the rep-
lication cohort and pyrosequencing was only performed
for a selection of miRNAs, the replication of the in-cis
miRNAs was performed separately for the two aberra-
tion types. Of the 70 in-cis miRNAs, 69 were present in
the replication cohort and thus targets of replication
(miR-624-5p was not expressed in the replication cohort).
The expression of the 69 in-cis miRNAs was tested for
association with copy number alterations by the same
approach as for the discovery cohort. Similarly, the ex-
pression of the 26 miRNAs selected for pyrosequencing
replication was tested for differential expression after
grouping the tumor samples into altered or non-altered
groups based on percentage methylation per CpG site
and using the normal samples as a reference. Among the
18 CpG sites, four probes represented two CpG sites in
the same promoter area (cg07641807 and cg23665802 on
chromosome 13 for assays 11 and 12, and cg00057966
and cg10530767 on chromosome 17 for assays 14 and
15, respectively). For these instances, a Wilcoxon rank-
sum test was performed separately, attaining the highest
P-values. In-cis miRNAs that were consistently statisti-
cally significant (P < 0.05) in the discovery and replica-
tion cohorts were considered replicated.
Test for differential miRNA expression in clinical and
molecular subgroups
To investigate differential expression of the identified
in-cis miRNAs in clinical subgroups and molecular
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Wilcoxon rank-sum test was used for two-group com-
parison and the Kruskal-Wallis one-way analysis of vari-
ance for three-group comparison (histological grade). A
significance level of P < 0.05 was chosen after FDR correc-
tion. A log-rank test was used for statistical comparison
of Kaplan-Meier survival curves (3 of the 89 samples in
the discovery cohort did not have survival data and were
thus excluded from this analysis).
Cell culture
MCF-7 cells [87,88] were purchased from Interlab Cell
Line Collection (ICLC, Genova, Italy) and cultured in
DMEM (1 g/l glucose; Sigma-Aldrich, St Louis, MO,
USA) supplemented with 10% fetal bovine serum (FBS),
2 mM L-glutamine and 1% penicillin/streptomycin.
JIMT-1 cells [89] were obtained from The German Col-
lection of Microorganisms and Cell Cultures (DSMZ,
Leibniz, Germany), and they were cultured in 1:1 Ham's
F-12/DMEM (4.5 g/l glucose) supplemented with 10% FBS,
10 μg/ml insulin, 2 mM L-glutamine and 1% penicillin/
streptomycin. KPL-4 cells [90] were a kind gift from
Prof. Junichi Kurebayashi (Kawasaki Medical School,
Japan), and they were cultured in DMEM (4.5 g/l glu-
cose) supplemented with 10% FBS, 2 mM L-glutamine
and 1% penicillin/streptomycin.
miRNA functional assays
For the functional assays, cells were transfected with
Dharmacon miRIDIAN microRNA mimics (20 nM;
Dharmacon, Lafayette, CO, USA) in 384-well plates using
SilentFect (Bio-Rad Laboratories, Hercules, CA, USA) as
described previously [9,91]. After 72 h incubation, cell
viability was assayed by CellTiter-GLO cell viability assay
(Promega Corp., Madison, WI, USA). The results were
Loess normalized [92] and log2-transformed. Values ±2 ×
SD, were considered as significant, which corresponded
to a threshold of |0.2|.
For protein lysate microarray analysis, cells were lysed
72 h after transfection and printed on nitrocellulose-
coated microarray FAST™ slides (Whatman Inc., Florham
Park, NJ, USA). Ki67, cPARP and p-AKT were detected
by staining the slides with Ki67 antibody (#M7240, Dako,
Glostrup, Denmark), cPARP antibody (#ab32064, Abcam,
Cambridge, UK), and p-AKT(S473) antibody (#9271, Cell
Signaling Technology Inc., Danvers, MA, USA), respect-
ively, followed by exposure to Alexa Fluor 680-tagged
secondary antibodies (Invitrogen Inc.). For total protein
measurement, the arrays were stained with Sypro Ruby
Blot solution (Invitrogen Inc.). The slides were scanned
with Tecan LS400 (Tecan Inc., Durham, NC, USA) micro-
array scanner and Odyssey Licor IR-scanner (LI-COR
Biosciences, Lincoln, NE, USA) to detect the Sypro,
Ki67, cPARP, and p-AKT signals. Array-Pro Analyzermicroarray analysis software (Median Cybernetics Inc.,
Bethesda, MD, USA) was used for analyzing the data.
The lysate microarray data were log2-transformed and
converted into z-scores by subtracting the mean of the
whole screen and dividing by the standard deviation of
the whole screen. Values ±2 × SD were considered as
significant, which corresponded to a threshold of |1.96|.Network analysis using IPA
Networks containing mRNAs correlated to candidate
miRNAs were generated with IPA (Ingenuity Systems) [93].
For each candidate miRNA, a dataset containing the list of
all the positively correlated (Spearman’s rho >0.3) and nega-
tively correlated (Spearman’s rho < -0.3) mRNAs (overlap-
ping both cohorts) was uploaded into the application. Each
identifier was mapped to its corresponding object in the
Ingenuity Knowledge Base. These molecules were over-
laid onto a global molecular network developed from in-
formation contained in the Ingenuity Knowledge Base,
and networks were then algorithmically generated based
on their connectivity. The confidence level was chosen
to include ‘experimentally observed’ and ‘high (predicted)’
relations.mRNA co-expression analysis using SEEK
SEEK [94] is a novel meta-analysis tool that incorporates
a large human microarray expression compendium. It
takes a set of gene identifiers as input and finds genes that
are co-expressed in the compendium with the input genes.
We first utilized SEEK to determine the extent to which
the mRNAs that we identified as positively or negatively
correlated to each candidate miRNA were supported by
other datasets. We input the list of correlated mRNAs as
query. The top 50 datasets related to the query were
dominated by breast cancer and included the mRNA
dataset we used in our analysis. We next retrieved the
co-expressed neighbors of the query genes, and per-
formed gene-set enrichment analysis on the neighbor set.
By selecting these genes rather than the query genes for
enrichment, we utilize the robustness due to the result of
integrating many microarray datasets. For the enrichment
analysis, the top 1,000 genes surrounding the query were
analyzed for overrepresentation in each of 1,371 Gene
Ontology biological processes (with human annotations).
Processes with a FDR-corrected P-value < 0.05 were con-
sidered statistically significant.Additional files
Additional file 1: Overview of the 70 in-cis miRNAs identified in the
discovery cohort. For each of the in-cis miRNAs, miRNA name, MIMAT
id, chromosomal location, copy number-miRNA expression correlation
and methylation-miRNA expression correlation with P-values and
Aure et al. Genome Biology 2013, 14:R126 Page 17 of 20
http://genomebiology.com/2013/14/11/R126aberration type are listed. The miRNAs in bold font are those that were
replicated in an independent cohort.
Additional file 2: Outline of the approach used to identify in-cis
miRNAs. The genomic locus (or loci) of all expressed miRNAs were
identified, and each sample was scored as altered or non-altered with
respect to DNA methylation status and copy number. Wilcoxon rank-sum
tests were applied to test whether alterations at the copy number or
methylation levels were associated with miRNA expression. In the discovery
cohort, 70 in-cis miRNAs were identified. Of these, 41 were replicated in an
independent cohort. *Accounting for the possibility that one mature miRNA
may have more than one genomic origin; this corresponds to 461 unique
miRNAs.
Additional file 3: Aberration pattern of miRNA family members
across the patients. The aberration pattern of 13 miRNAs that are
members of the five families listed in Table 1 are shown for the patients
in the discovery cohort (n = 89; only aberrations of the type
hypomethylation or gain are shown). miRNA family name, miRNA ids and
genome coordinates are listed. The color coding represents aberration
type for single patients (see legend under the table). One ‘Overall result’
row is indicated per miRNA family, which represents the total activating
aberration state of a patient for that miRNA family.
Additional file 4: Scatterplots comparing copy number-expression and
methylation-expression correlation in the discovery and replication
cohort. (a) Scatterplot representing correlation between copy number and
miRNA expression for the 69 in-cis miRNAs in the discovery and replication
cohorts (one in-cis miRNA was not expressed in the replication cohort).
(b) Scatterplot representing correlation between methylation status and
miRNA expression in the discovery and replication cohorts for the 26
miRNAs assessed by pyrosequencing in the replication cohort. Black circles
represent miRNAs that were initially identified in the discovery cohort and
later confirmed in the replication cohort (with respect to aberration type
and association to expression). Open circles represent miRNAs that were
not confirmed in the replication cohort. Corr, Spearman correlation
coefficient.
Additional file 5: Replicated miRNAs and association with clinical
parameters (in at least one cohort). Shown are all of the replicated in-cis
miRNAs that were found significantly differentially expressed between clinical
or molecular subtypes in at least one of the two cohorts. Significant P-values
are highlighted in bold (P < 0.05).
Additional file 6: Boxplots showing miRNA expression within
patient aberration groups for four candidate miRNAs. (a) miR-21-3p
expression in the discovery and replication cohort. (b) miR-151a-5p expression
in the discovery and replication cohort. (c) miR-148b-3p expression in
the discovery and replication cohort. (d) let-7e-3p expression in the discovery
and replication cohort. The P-values are from Wilcoxon rank-sum tests.
Hypermet, hypermethylated.
Additional file 7: Genes correlated to candidate miRNAs. For each of
the four candidate miRNAs, the genes that were consistently found
correlated (miRNA-mRNA Spearman correlation > |0.3|) in both the
discovery and replication cohorts are listed. The genes are sorted by
increasing correlation based on the discovery cohort’s correlation values.
Additional file 8: Enrichment of genes co-expressed with correlated
genes. For each of the four candidate miRNAs, the positively or
negatively correlated genes were used as query input to the SEEK tool
[94]. The set of co-expressed genes thus identified was used for functional
enrichment analysis. Gene Ontology biological process terms that were
found enriched among the co-expressed genes are listed together with the
FDR-corrected P-values.
Additional file 9: Networks of genes correlated to the four
candidate miRNAs. The list of correlated genes was imported into IPA,
and networks were generated based on known and predicted
associations and interactions of the corresponding proteins. Solid lines
represent direct relationships and dotted lines represent indirect
relationships. Proteins colored in red are positively correlated to the
miRNA (Spearman’s rho >0.3), and proteins colored in green are
negatively correlated (Spearman’s rho < -0.3). White proteins are not
among the genes found correlated to a miRNA. The legend shows protein
function. Network of proteins (genes) correlated to (a) miR-148b-3p,(b) let-7e-3p and (c) miR-21-3p. The networks were generated
through the use of IPA (Ingenuity® Systems [93]).
Additional file 10: Discovery cohort data (575 miRNAs × 89
patients). The miRNA copy number, methylation and expression data
analyzed for the discovery cohort are provided in different sheets.
Additional file 11: Replication cohort data (69 miRNAs × 123
patients). The miRNA copy number, methylation and expression data
analyzed for the replication cohort are provided in different sheets.
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